Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson’s disease

被引:0
|
作者
Huimin Chen
Jinping Fang
Fangfei Li
Liyan Gao
Tao Feng
机构
[1] Capital Medical University,Department of Neurology, Center for Neurodegenerative Disease, Beijing Tiantan Hospital
[2] Beijing institute for brain disorders,Parkinson’s Disease Center
[3] China National Clinical Research Center for Neurological Diseases,undefined
来源
Neurological Sciences | 2015年 / 36卷
关键词
Parkinson’s disease; Wearing-off; Levodopa; Safe dosage;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of this study was to investigate the risk factors of wearing-off phenomenon in Parkinson’s disease (PD) and propose safe dosage of levodopa to reduce wearing-off development based on Chinese cohort. Patients with PD who had taken levodopa (l-dopa) for at least 1 month were recruited. Wearing-off was diagnosed based on validated Chinese version of a patient self-rated 9-question Wearing-Off Questionnaire (WOQ-9) and clinical definition. Eleven variables (gender, disease duration at l-dopa initiation, disease duration at assessment, age at onset, age at assessment, H-Y stage, UPDRS III, l-dopa daily total dosage and dosage adjusted to weight, duration of l-dopa treatment, initial drug recipe) were included in our analysis. Univariate analysis, multivariate logistic regression analysis and decision tree classification model(DTC) were used to detect risk factors of wearing-off. Receiver operating characteristic (ROC) curve and DTC were used to investigate cut-off value of l-dopa to best predict wearing-off. Two hundred and thirty-four patients were investigated in our study, among whom 111 developed wearing-off. Patients with wearing-off tended to receive higher l-dopa dosage and endure longer duration of l-dopa treatment. l-Dopa dosage as 281 mg/day and 4.2 mg/kg/day by ROC, as well as 269 mg/day and 3.2 mg/kg/day by DTC were cut-off values for wearing-off. l-Dopa dosage and duration of l-dopa treatment were related to increased wearing-off development. Cumulative l-dopa dosage and l-dopa daily dosage were better predictive of wearing-off. Inadequate evidence was present for delayed l-dopa initiation. l-Dopa daily dosage no more than 275 mg or 4.2 mg/kg was regarded as safe.
引用
收藏
页码:1217 / 1223
页数:6
相关论文
共 50 条
  • [41] Entacapone decreases axial symptoms and tremor in levodopa-treated Parkinson's disease patients experiencing wearing-off symptoms
    Brooks, DJ
    Kuoppamäki, M
    Vahteristo, M
    [J]. MOVEMENT DISORDERS, 2005, 20 : S120 - S120
  • [42] Frequency of Wearing-Off Symptoms in Parkinson's disease Fluctuators: An on/off evaluation
    Perepezko, K.
    Hinkle, J.
    Mills, K.
    Pontone, G.
    [J]. MOVEMENT DISORDERS, 2020, 35 : S344 - S344
  • [43] Role of the pharmacist in the effective management of wearing-off in Parkinson's disease
    Simonson, William
    Hauser, Robert A.
    Schapira, Anthony H. V.
    [J]. ANNALS OF PHARMACOTHERAPY, 2007, 41 (11) : 1842 - 1849
  • [44] Validation of the "QUICK" questionnaire - A tool for diagnosis of "Wearing-Off' in patients with Parkinson's disease
    Martinez-Martin, Pablo
    Tolosa, Eduardo
    Hernandez, Basilio
    Badia, Xavier
    [J]. MOVEMENT DISORDERS, 2008, 23 (06) : 830 - 836
  • [45] Absence of wearing-off in Parkinson's disease patients with treatment beyond 10 years
    Wei, Q.
    Ou, R.
    Wu, Y.
    Yuan, X.
    Hou, Y.
    Liu, H.
    Zhang, L.
    Chen, Y.
    Cao, B.
    Chen, X.
    Shang, H.
    [J]. MOVEMENT DISORDERS, 2018, 33 : S149 - S149
  • [46] Efficacy of Levodopa/Carbidopa/Entacapone Replacement of Levodopa/Dopa Decarboxylase Inhibitors in Treatment of Chinese Parkinson's Disease Patients with Wearing-off: A Multicenter, Randomized Controlled, Open Label Study
    Yu, C. Y.
    Liu, W. G.
    Gong, A. P.
    Shen, L. H.
    Huang, H.
    Zhao, Y.
    Liu, C. F.
    [J]. MOVEMENT DISORDERS, 2023, 38 : S60 - S61
  • [47] The efficacy of istradefylline for treating mild wearing-off in Parkinson's disease
    Kitagawa, M.
    Yabe, I.
    Takahashi, I.
    Matushima, M.
    Sasaki, H.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 364 - 365
  • [48] Rotigotine for anxiety during wearing-off in Parkinson’s disease with dementia
    Alessandra Fanciulli
    Francesca Assogna
    Carlo Caltagirone
    Gianfranco Spalletta
    Francesco E. Pontieri
    [J]. Aging Clinical and Experimental Research, 2013, 25 : 601 - 603
  • [49] Rotigotine for anxiety during wearing-off in Parkinson's disease with dementia
    Fanciulli, Alessandra
    Assogna, Francesca
    Caltagirone, Carlo
    Spalletta, Gianfranco
    Pontieri, Francesco E.
    [J]. AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2013, 25 (05) : 601 - 603
  • [50] An open-label evaluation of the tolerability and safety of Stalevo® (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off
    Koller, W
    Guarnieri, M
    Hubble, J
    Rabinowicz, AL
    Silver, D
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2005, 112 (02) : 221 - 230